Project Grant R01HL175295
Award Date 9/1/25
Completion Date 5/31/30
Dollars Obligated $784K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The federal Project Grant award of $131,886 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, to conduct research on the use of bioimpedance as a tool to assess volume status and predict cardiovascular outcomes in patients with chronic kidney disease. The study aims to 1) examine the predictive capacity of changes in volume measured by bioimpedance for...
- This Project Grant award of $777,258 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to advance the understanding of heart failure in hypertrophic cardiomyopathy (HCM) and evaluate the impact of the cardiac myosin inhibitor mavacamten compared to surgical myectomy. The research, to be conducted by Beth Israel Deaconess Medical Center, Inc. from February 2025 through January 2030, will utilize cardiac magnetic resonance imaging...
- The Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500 to Brigham & Women's Hospital Inc. to develop and validate a quantitative marker of pulmonary microvascular injury and explore the correlation between microvascular volume loss and the longitudinal progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The research leverages an AI-based algorithm to assess vascular...
- This federal Project Grant award of $193,984 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the interplay between inflammation, angiogenesis, myocardial perfusion, and myocardial function in patients with advanced chronic kidney disease (CKD). The project, conducted by Brigham & Women's Hospital Inc., aims to mechanistically explore cardiovascular health before and after kidney transplantation. Key objectives...
- This Project Grant award, valued at $167,400.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will support research by Brigham & Women's Hospital Inc. to investigate how the immune mediator CD70 regulates endothelial metabolism and function, with the goal of identifying novel therapeutic targets for atherosclerotic cardiovascular disease. The 5-year project will comprehensively examine the role of CD70 in impairing endothelial...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to discover novel biomarkers and biological mechanisms underlying early-stage heart failure (HF). The $147,486 award to Duke University will support the development of an automated computational phenotype to identify early-stage HF, which will then be applied to large population cohorts. The research aims to leverage multi-omics data integration and...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). This 7-year grant, effective February 1, 2025, will support research to understand the role of macrophages in preserving cardiovascular health, illuminating their contributions to cardiovascular disease, and...
- This Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The $138,523 award to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) will fund research to investigate the distinct mechanisms underlying medial and intimal calcification in blood vessels, which are associated with increased cardiovascular disease risk. The research aims to systematically...
- This federal Project Grant award of $169,020.00 was provided by the National Heart Lung and Blood Institute (NHLBI), which operates under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pennsylvania investigating the impact of obesity and diabetes on coronary microvascular defects in heart failure with preserved ejection fraction (HFpEF). The research will use an animal model of HFpEF to compare the temporal progression...
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...